ArticleDermatology and therapy2025
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.
Joseph F Merola et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled ittrialcites it